536 related articles for article (PubMed ID: 18958156)
21. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
23. CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.
Shi CJ; Gao J; Wang M; Wang X; Tian R; Zhu F; Shen M; Qin RY
World J Gastroenterol; 2011 Jun; 17(24):2965-71. PubMed ID: 21734809
[TBL] [Abstract][Full Text] [Related]
24. Research progression of CD133 as a marker of cancer stem cells.
Zhang H; Li SY
Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
[TBL] [Abstract][Full Text] [Related]
25. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Ke CC; Liu RS; Yang AH; Liu CS; Chi CW; Tseng LM; Tsai YF; Ho JH; Lee CH; Lee OK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):61-71. PubMed ID: 23081821
[TBL] [Abstract][Full Text] [Related]
26. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy.
Wang L; Huang X; Zheng X; Wang X; Li S; Zhang L; Yang Z; Xia Z
Int J Biol Sci; 2013; 9(5):472-9. PubMed ID: 23781140
[TBL] [Abstract][Full Text] [Related]
27. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.
Zhang Q; Shi S; Yen Y; Brown J; Ta JQ; Le AD
Cancer Lett; 2010 Mar; 289(2):151-60. PubMed ID: 19748175
[TBL] [Abstract][Full Text] [Related]
28. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
[TBL] [Abstract][Full Text] [Related]
29. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
30. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
31. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
32. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
33. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
Cui F; Wang J; Chen D; Chen YJ
Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
[TBL] [Abstract][Full Text] [Related]
34. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
35. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K
Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953
[TBL] [Abstract][Full Text] [Related]
36. Growth kinetics of CD133-positive prostate cancer cells.
Reyes EE; Kunovac SK; Duggan R; Kregel S; Vander Griend DJ
Prostate; 2013 May; 73(7):724-33. PubMed ID: 23138940
[TBL] [Abstract][Full Text] [Related]
37. Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.
Chen KL; Pan F; Jiang H; Chen JF; Pei L; Xie FW; Liang HJ
Clin Exp Metastasis; 2011 Dec; 28(8):751-63. PubMed ID: 21750907
[TBL] [Abstract][Full Text] [Related]
38. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
39. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
40. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
